MagBio Genomics said on Monday that it has received US Food and Drug Administration 510(k) clearance, as well as CE marking, for its MagXtract Collection Tube for viral sample collection.

Adaptive Biotechnologies on Monday said that it has signed a nondilutive financing agreement with investment firm OrbiMed that will give it access to as much as $250 million in exchange for a portion of its revenues.

On September 9, 2022, MGI Tech Co., Ltd. was listed on the STAR Market. The stock name is Huada Zhizao, the stock code is 688114. SH, with the issue price is 87.18 CNY / share, and the opening price is 107 CNY / share. MGI is an affiliated company of the Listed Company BGI.

Becton Dickinson and Viramed Biotech each gained US Food and Drug Administration 510(k) clearance in August for panels to differentiate pathogenic illnesses, and a Werfen subsidiary got the go-ahead for a panel used to evaluate coagulation pathways and Vitamin K antagonist treatment.

Morgan Health, JPMorgan Chase's healthcare-focused business unit, said on Thursday that it had invested $20 million in at-home testing company LetsGetChecked.

Chris Lee aims to transform healthcare fundraising through VentureBlick’s fundraising platform and professional community

The US Department of Health and Human Services announced on Wednesday that it has authorized the Food and Drug Administration to issue emergency use authorizations for monkeypox tests.

France's Lesaffre said on Wednesday that it has acquired genome engineering firm Recombia Biosciences.

UK-based molecular diagnostics system developer QuantuMDx said on Tuesday that it has entered into a global R&D, manufacturing, and commercial partnership agreement with Sansure Biotech aimed at commercializing its Q-POC system and assays in China.

Illumina said on Tuesday that it has received a decision from the European Commission that will prohibit the firm from keeping liquid biopsy maker Grail.

The H1 reports of Chinese listed companies in 2022 have all been revealed.

Stock price review: centralized procurement VS epidemic, differentiated growth and excess earnings. Two peaks in January 2022 and March-April 2022. IVD, low-value consumables, etc. performed prominently, mainly driven by the epidemic

FDA has issued an emergency use authorization for both the Pfizer-BioNTech and Moderna bivalent COVID-19 boosters.

The use of biomarker and genetic tests during pregnancy is now extremely widespread. But what if both parents’ genes were broadly analyzed for possible risks prior to conception?

On September 1, Nanjing Vazyme Biotech Co.,Ltd. signed a strategic cooperation agreement with Henan Medical Biological Testing Company.